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Abstract
Background: Super-infection in adult bacterial meningitis (ABM) is a condition wherein the cerebrospinal fluid
(CSF) grows new pathogen(s) during the therapeutic course of meningitis. It is an uncommon but clinically
important condition rarely examined in literature.
Methods: Twenty-seven episodes of super-infection states in 21 ABM patients collected in a 9.5-year study period
(January 2001 to June 2010) were evaluated. The clinical characteristics, implicated pathogens, results of
antimicrobial susceptibility tests, and therapeutic outcomes were analyzed.
Results: Twenty-one patients (13 men, 8 women) aged 25-73 years (median, 45 years) had post-neurosurgical state
as the preceding event and nosocomial infection. The post-neurosurgical states included spontaneous intracranial
hemorrhage (ICH) with craniectomy or craniotomy with extra-ventricular drainage (EVD) or ventriculo-peritoneal
shunt (VPS) in 10 patients, traumatic ICH with craniectomy or craniotomy with EVD or VPS in 6 patients,
hydrocephalus s/p VPS in 2 patients, and one patient each with cerebral infarct s/p craniectomy with EVD,
meningeal metastasis s/p Omaya implant, and head injury. All 21 patients had EVD and/or VP shunt and/or Omaya
implant during the whole course of ABM. Recurrent fever was the most common presentation and the implicated
bacterial pathogens were protean, many of which were antibiotic resistant. Most patients required adjustment of
antibiotics after the pathogens were identified but even with antimicrobial therapy, 33.3% (7/21) died. Morbidity
was also high among survivors.
Conclusions: Super-infection in ABM is usually seen in patients with preceding neurosurgical event, especially
insertion of an external drainage device. Repeat CSF culture is mandatory for diagnostic confirmation because most
of the implicated bacterial strains are non-susceptible to common antibiotics used. Unusual pathogens like
anaerobic bacteria and fungi may also appear. Despite antimicrobial therapy, prognosis remains poor.
Background
Super-infection in adult bacterial meningitis (ABM) is a
condition in which the cerebrospinal fluid (CSF) grows
new pathogen(s) during the therapeutic course of
meningitis [1,2]. This uncommon situation is rarely
examined solely in overview studies of ABM [3,4]. In
ABM management, early and appropriate antibiotic use
is an important strategy for better outcomes [5-7].
However, super-infection may cause a dilemma in anti-
biotic choice because starting a new antimicrobial regi-
men for this complicated condition during the
therapeutic course of ABM is a difficult decision. To
better delineate the clinical characteristics of super-
infection in ABM, this study analyzed the clinical char-
acteristics and therapeutic outcomes of ABM patients
with super-infection.
Methods
The medical and microbiological records for CSF of all
adult patients with bacterial meningitis admitted to
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2482-bed acute-care teaching hospital and the largest
tertiary care center in southern Taiwan, from January
2001 to June 2010 (9.5 years) were retrospectively
reviewed. The hospital’s Ethics Committee approved the
study (IRB 99-1897C).
Diagnosis of ABM was based on: i) age ≥17 years; ii)
positive CSF culture in patients with clinical presenta-
tion of acute meningitis (i.e. fever, altered consciousness,
or seizure); and iii) at least one of the following CSF
parameters: leukocyte count >0.25 × 10
9/L with predo-
minant polymorphonuclear cells; CSF lactate concentra-
tion >3.5 mmol/L; glucose ratio (CSF glucose/serum
glucose) <0.4; or CSF glucose concentration <2.5 mmol/
L if no simultaneous blood glucose was determined
[3,4]. “Super-infection” in ABM was defined as a condi-
tion wherein CSF grew new pathogen(s) during the ther-
apeutic course of an existing bacterial meningitis [1,2].
For this study, ABM was classified as either nosoco-
mial or community-acquired. Nosocomial meningitis
was defined as positive bacterial infection not present
on hospital admission, clinical evidence of infection no
sooner than 48 hours after admission, or clinical evi-
dence of meningitis within a short period of time, i.e.
within one month after discharge from the hospital
where the patient received an invasive procedure, espe-
cially a neurosurgical one. Otherwise, the patient was
considered as having “community-acquired” infection.
Patients who developed meningitis related to head
trauma with skull fractures or neurosurgical procedures
were classified as “post-neurosurgical” meningitis.
Otherwise, patients who demonstrated no clear distinc-
tive disease characteristics and who had not undergone
any invasive procedures were classified as “spontaneous”
meningitis. “Mixed-infection” was defined as at least two
bacterial organisms isolated concomitantly from CSF
culture [4,8].
During the study period, intravenous administration of
vancomycin with either a 3
rd -o r4
th- generation cepha-
losporin (e.g. ceftriaxone, ceftazidime, or cefepime) were
the initial empiric antibiotics used to treat adult patients
with clinical evidence of bacterial meningitis. Further
antibiotic adjustment was guided by results of pathogen
identification and antibiotic susceptibility tests. Antibiotic
susceptibility of the isolated pathogen was tested using
the Kirby-Bauer diffusion method (BBL, Muller-Hinton
II agars; Becton Dickinson Microbiology Systems, Cock-
eysville, MD) while bacterial susceptibility to antimicro-
bial agents was determined according to criteria of the
National Committee for Clinical Laboratory Standards
(CLSI). The therapeutic results were evaluated by using
Glasgow Outcome Scale (GOS) [9]: score 1 = death,
score 2 = persistent vegetative state, score 3 = severe dis-
ability, score 4 = moderate disability, score 5 = good
recovery. Scores of 1-3 were classified as “poor prog-
nosis” while scores of 4 and 5 were “good prognosis”.
For comparative analysis, the patients were divided
into fatal and non-fatal groups. Data such as sex, type of
infection, underlying conditions, and clinical manifesta-
tions between these two patient groups were analyzed
by Fisher’s exact test. Age between the two groups was
analyzed by Mann-Whitney U test.
Results
During the study period, 21 ABM patients aged 25-73
years (median 45 years), including 13 men and 8
women, had super-infection. Their basic clinical and
laboratory data are listed in Tables 1 and 2. All had
post-neurosurgical state as the preceding event and had
contracted the infection nosocomially. The post-neuro-
surgical states included spontaneous intracranial hemor-
rhage (ICH) with craniectomy or craniotomy with extra-
ventricular drainage (EVD) or ventriculo-peritoneal
shunt (VPS) in 10 patients (Cases 2-4, 9-11, 14, 17, 20,
21), traumatic ICH with craniectomy or craniotomy
with EVD or VPS in 6 patients (Cases 5, 6, 12, 13, 16,
18), hydrocephalus s/p VPS in 2 patients (Cases 7, 15),
cerebral infarct s/p craniectomy with EVD in Case 1,
meningeal metastasis s/p Omaya implant in Case 8, and
head injury in Case 19. All 21 patients had undergone
EVD and/or VPS and/or Omaya implant during the
whole clinical course of ABM. The underlying medical
conditions included diabetes mellitus in 3 patients
(Cases 3, 10, 20), lung cancer in Case 8, brain tumor in
Case 11, and liver cirrhosis in Case 21.
There were 27 episodes of super-infection in the 21
ABM patients. The initial and subsequently implicated
pathogens are listed in Table 1. Eight patients (Cases 1-
8) were converted from Gram-positive (G(+)) pathogen
infection to Gram-negative (G(-)) pathogen infection
and two (Cases 9 and 10) were converted from G(-)
pathogen to G(+) pathogen infection. Six patients (Cases
11-16) were converted from G(-) pathogen infections to
another G(-) pathogen infection. Cases 17-21 had other
converted states of implicated pathogens, while Case 18
had a more complicated conversion in different CSF
cultures with different combinations of implicated
pathogens noted in each culture.
Of the 27 episodes of super-infection, the time interval
from finding the previous pathogen to detecting a new
pathogen, i.e. appearance of super-infection, ranged
from 3 to 90 days. Changes in clinical and laboratory
evidence of super-infection were noted in 20 of the 27
episodes. Recurrent fever was the most common and
f o u n di n1 7e p i s o d e s( C a s e s1 - 3 ,5 - 8 ,1 0 ,1 1 ,1 4 - 1 6 ,1 8 ,
20), The other new presentations were CSF pleocytosis
in 5 episodes (Cases 1, 3, 7, 19, 20), peripheral leukocy-
tosis in 3 episodes (Cases 1, 13, 20), appearance of
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Page 2 of 8Table 1 Clinical data and implicated pathogens in the super-infections of the study patients with adult bacterial meningitis
Case Gender Age
(years)
Underlying
condition
Initial pathogen
(s)
Antibiotics Management Interval*
(days)
New
presentation
New pathogen(s) Antibiotics Management Survived
More than 7 days interval*
Gram (+) ® G (-) or G (-) ® G (+)
1 M 55 Infarct, craniectomy,
EVD
Staphylococcus
aureus
§
LZD+EPM Removed EVD
® new EVDs
61 Fever,
leukocytosis,
CSF pleocytosis
ESBL-Escherichia coli MEP Removed EVD No
2 F 48 SICH, craniectomy,
EVD
Staphylococcus
aureus
§
VA+CAZ Removed EVD
® craniotomy,
new EVDs
34 Fever,
hydrocephalus
Stenotrophomonas
maltophilia
#
MOX+TMP
+ TIG+
ATM
Removed EVD ®
New EVD ®
removed EVD ®
VP shunt
Yes
3 F 55 DM, SICH,
craniotomy, VPS
Staphylococcus
aureus
§
VA Removed VPS,
debridement ®
new EVD
11 Fever, CSF
pleocytosis
Acinetobacter
baumannii
LZD+MEP New EVD ®
ventriculo-pleural
shunt
Yes
4 F 41 SICH, craniectomy,
EVD
Staphylococcus
epidermidis
§
VA Craniotomy, EVD
® VPS
47 No Enterobacter cloacae
+ Pseudomonas
aeruginosa
CAZ Removed VPS No
5 M 73 TICH, craniectomy,
EVD (removed)
Coagulase-
negative
staphylococci
§
VA New EVD 9 Fever, seizure,
altered
consciousness
Enterobacter cloacae ROC Removed EVD ®
VP shunt
Yes
6 M 46 TICH, craniectomy,
VPS
Coagulase-
negative
staphylococci
§
VA Externalisation
VPS ® removed
VPS ® new
EVDs
46 Fever Coagulase-negative
staphylococci
§ +
Acinetobacter
baumannii
MEP Removed EVD ®
new EVDs ® VP
shunt
Yes
7 M 34 Hydrocephalus, VPS Staphylococcus
epidermidis
§
VA Removed VPS,
New EVDs
28 Fever, CSF
pleocytosis
Acinetobacter spp CEF Removed EVD ®
New EVD ®
removed ® VPS
Yes
8 F 45 Lung cancer,
meningeal
metastasis, Omaya
implant, infection
Coagulase-
negative
staphylococci
§
VA Debridement,
removed Omaya
implant
42 Fever Acinetobacter spp CAZ Yes
9 F 48 Brain tumor, SICH,
craniectomy
Pseudomonas
aeruginosa
CEF New EVD 14 No Enterococcus spp AMP+CEF New EVD ®
Removed EVD
Yes
10 M 67 DM, SICH, VPS,
craniotomy, EVD
Acinetobacter
baumannii
MEP Removed VPS,
new EVDs
41 Fever Staphylococcus
aureus
§
VA Removed EVD No
Gram (-) ® G (-)
11A M 45 Brain tumor, SICH,
craniectomy, VPS
Serratia
marcescens
@
MEP Removed VPS,
new EVD
29 Fever, reduced
CSF glucose
Stenotrophomonas
maltophilia
MOX+TMP Removed EVD ®
new EVD
Treated
11B 90 No Candida glabrata FLU+AMB Treated
11C 48 Fever Stenotrophomonas
maltophilia
#
TMP+TIG No
12 M 25 TICH, craniectomy,
EVD
Pseudomonas
aeruginosa
CAZ New EVDs 37 No Pseudomonas
aeruginosa + ESBL-
Proteus mirabilis
MEP Removed EVD Yes
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8Table 1 Clinical data and implicated pathogens in the super-infections of the study patients with adult bacterial meningitis (Continued)
13 M 25 TICH, craniotomy,
VPS
Pseudomonas
putida
CAZ Removed VPS,
new EVD
23 Leukocytosis Acinetobacter spp
@ MEP+SBM Removed EVD ®
New EVDs ® VPS
Yes
14 M 64 SICH, VPS Serratia marcescens VA + MEP Removed VPS ®
new EVD
8 Fever, altered
consciousness,
hydrocephalus
Acinetobacter
baumannii
@
MEP+SBM+
TIG+CST
Removed EVD ®
new EVDs ® VP
shunt
Yes
15A F 71 Old meningitis,
hydrocephalus, VPS
Morganella
morganii
CAZ Externalization
VPS® removed
® new VPS
47 Fever Proteus mirabilis
@ MEP Removed VPS Treated
15B 40 Fever Glucose non-
fermenting bacilli
@
MEP+SBM Scalp debridement
® VPS
Yes
16 M 31 TICH, craniotomy,
EVD (removed)
Stenotrophomonas
maltophilia
CAZ New EVDs 60 Fever Stenotrophomonas
maltophilia +
Pseudomonas
aeruginosa
MEP+CIP New EVDs ® VPS
® removed VPS ®
Omaya implant
Yes
Others
17 F 58 SICH, EVD Staphylococcus
epidermidis
§+
Acinetobacter
lwoffii
VA+ROC+
CM
Removed EVD,
new EVD
28 No Staphylococcus
epidermidis
§+
Pseudomonas
aeruginosa
CAZ Removed EVD ®
New EVD ® VPS
Yes
18A M 48 TICH, craniectomy,
EVD (removed)
Escherichia coli MEP New EVDs ®
craniotomy
36 Scalp wound
infection
Candida tropicalis FLU removed EVD,
debridement
Treated
18B 9N o Escherichia coli+
Acinetobacter
bauamnnii+
Enterococcus faecalis
AMP Debridement ®
new EVD
Treated
18C 11 Fever Staphylococcus
aureus
§+
Acinetobacter
baumannii
VA+IPM Removed EVD, new
EVD
Treated
18D 14 Fever Stenotrophomonas
maltophilia
CIP Removed EVD, new
EVD ® removed
Yes
19 M 58 Head injury Viridan
streptococci
VA+ROC 8 Hydrocephalus,
ventriculitis,
CSF pleocytosis
Prevotella+ Veilonella
+ Fusobacterium
VA+ROC+
MET
New EVD No
Less than 7 days interval
20 F 64 DM, VHD, SICH,
craniectomy, EVD
Escherichia coli+
Enterococcus
faecalis
VA+CAZ Removed EVD,
New EVD
3 Fever,
leukocytosis,
CSF pleocytosis
Enterobacter
cloacae
#@
VA+CAZ Removed EVD ®
VPS
No
21 M 49 Liver cirrhosis, SICH,
craniectomy, EVD
(removed)
Coagulase-
negative
staphylococci
§
VA New EVD 5 No Enterobacter
aerogenes
CEF New EVDs No
§Oxacillin-resistant;
#change antibiogram during treatment;
@ cephalosporin-resistant; *the time interval from the finding of previous pathogen(s) to the detection of the following new pathogen(s).
Abbreviations: M, male; F, female; EVD, external ventricular drainage; SICH, spontaneous intra-cranial hemorrhage; DM, diabetes mellitus; VPS, ventriculo-peritoneal shunt; TICH, traumatic intra-cranial hemorrhage;
ESBL, extended spectrum b-lactamase; LZD, linezolid; EPM, entrapenem; VA, vancomycin; CAZ, ceftazidime; CEF, cefepime; MEP, meropenem; ROC, ceftraixone; CM, chloroamphenicol; CSF, cerebrospinal fluid; MOX,
moxifloxacin; TMP, trimethoprim-sulfamethoxazole; FLU, fluconazole; AMB, amphotericin B; TIG, tigecycline; SBM, sulbactam; ATM, aztreonam; CST, colistin; AMP, ampicillin; MET, metronidazole
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8hydrocephalus in 3 episodes (Cases 2, 14, 19), altered
consciousness in 2 episodes (Cases 5, 14), seizure in 1
episode (Case 5), scalp wound infection in 1 episode
(Case 18) and appearance of ventriculitis in 1 episode
(Case 19). The other 7 episodes without new clinical
presentations were detected by regular CSF check-up
studies.
Results of antibiotic susceptibilities of the implicated
pathogens are listed in Table 2. Initial antibiotic use and
the adjusted antibiotic after identification of the patho-
gens in the super-infections are listed in Table 1. The
choices were guided by results of antimicrobial suscept-
ibility tests. In addition to medical treatment, the other
20 patients except Case 8 had undergone removal of
EVD or VPS and insertion of a new EVD or VPS.
With medical treatment, 14 patients survived while 7
d i e d .F o u ro ft h e1 4s u r v i v o r s( C a s e s2 ,6 ,7 ,a n d1 5 )
had clear consciousness while the other 10 had dis-
turbed consciousness. One of the four survivors with
clear consciousness (Case 7) had full recovery while the
other three had quadriparesis. With GOS assessment,
Case 7 had good prognosis, while the other 20 had poor
prognosis. Comparative results between the fatal and
non-fatal groups showed no significant clinical factors
(Table 3).
Discussion
There is an increasing number of ABM patients with
preceding neurosurgical condition, according to previous
epidemiologic studies [4,14-16]. A preceding neurosurgi-
cal state is associated with mixed, relapsing, or recurrent
infectious state of ABM [3,4,8]. In the current study, all
21 ABM patients with super-infection had a neurosurgi-
cal condition as the preceding event and all had under-
gone a procedure involving the insertion of a
neurosurgical device during the entire clinical course.
This may imply that neurosurgical device insertion is an
important event in the development of super-infection.
Aside from this pre-condition, 69% (18/26) of the super-
infection episodes occurred despite an antibiotic-treat-
ment course for bacterial meningitis longer than two
weeks (Table 1). Thus, the occurrence of super-infection
during ABM treatment may also suggest an inadequate
infectious control program of the hospital.
Due to the preceding neurosurgical condition and
existing bacterial meningitis, the clinical presentation of
super-infection in ABM may be obscured. In the 27 epi-
sodes of the 21 ABM patients in this study, new evi-
dence of meningitis is noted in 74.1% (20/27).
Recurrence of fever was the most common, occurring in
63.0% (17/27) of the episodes. Other new evidences of
meningeal infection included CSF pleocytosis, peripheral
leukocytosis, and altered consciousness. All of these pre-
sentations are not unique and can be found in other
infectious states, including central nervous system infec-
tions [6]. Therefore, a high index of suspicion is impor-
tant because thus far, only repeat CSF follow-up studies
and bacterial culture are the most important steps to
confirm the diagnosis of ABM with super-infection.
Staphylococcal species were the most common G(+)
pathogens implicated in both initial ABM and ABM
with super-infection in the 21 study patients (Table 1).
This finding is consistent with previous reports [17-19]
that have shown the high prevalence of staphylococcal
infection in this specific group of patients. Most of the
implicated staphylococcal pathogens shown in this study
were methicillin-resistant. However, the presence of
these resistant G(+) strains is not a therapeutic problem
because intravenous vancomycin is one of the empiric
antibiotics for ABM treatment in the hospital [4,16].
It is known that early and appropriate antimicrobial
use is of strategic importance in managing ABM [4,5,7].
Early diagnosis of super-infection in the therapeutic
course is also important because most patients need an
adjustment of antimicrobial agents after identification of
the newly-implicated pathogens (Table 1). Such adjust-
ments are important in Cases 1-10 because of the con-
version from G(+) to G(-) bacterial pathogens in Cases
1-8 and from G(-) to G(+) pathogens in Cases 9 and 10.
Another important therapeutic consideration in antibio-
tic use is the emergence of multi-drug resistant bacterial
strains in G(-) ABM [11-13,20-25]. This problem is nota-
ble especially in patients with underlying G(-) ABM and a
super-infection caused by another G(-) pathogen. Case 12
had ESBL-Proteus mirabilis infection, Cases 13 and 14 had
multi-drug resistant (MDR) Acinetobacter spp. infections,
and Case 16 had ceftazidime- and cefepime-resistant Pseu-
domonas aeruginosa infection. All four cases needed anti-
biotic adjustments for the corresponding newly-cultured
bacterial pathogens. The emergence of Stenotrophomonas
maltophilia as the implicated pathogen was noted in
Cases 2, 11, and 18. Its emergence has caused a therapeu-
tic challenge because it is usually not susceptible to tradi-
tional antibiotics used in ABM treatment [24,25].
Presently, trimethoprime-sulfamethoxazole or quinolones
are the antimicrobial agents of choice [23,24].
In this study, another observed problem is the change
of antibiotic susceptibilities during the therapeutic
course of super-infection by G(-) pathogens (Table 2).
MDR Stenotrophomonas maltophilia-strain emerged in
Case 2 and meropenem-resistant A. Baumannii strain in
Case 3. Other resistant strains that emerged during the
therapeutic course of super-infection were ceftazidime-
resistant A. baumannii in Case 6, ceftazidime-resistant
Pseudomonas aeruginosa in Cases 9 and 12, and ceftazi-
dime-resistant Enterobacter cloacae in Case 20. All of
these changes in antibiotic susceptibilities required an
adjustment of antimicrobial agents. In the super-
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Page 5 of 8Table 2 Antibiogram of implicated pathogens in the super-infections of the study patients with adult bacterial
meningitis (n = 21)
Case Pathogens ROC CAZ MAX MEP CIP TIG TMP-SMX AMP- SBM
1 ESBL-Escherichia coli RRR S S
2 Stenotrophomonas maltophilia SR
RR
3 Acinetobacter baumannii ISSR S
SS RR S
4 Enterobacter cloacae SS S
Pseudomonas aeruginosa SS SS
5 Enterobacter cloacae SS SS
6 Acinetobacter baumannii SS SS
ISSS
7 Acinetobacter spp IS SS S S
8 Acinetobacter spp SSS SS S
9 Pseudomonas aeruginosa SS SS
RS S
10 Acinetobacter baumannii SS SS
11A Serratia marcescens IR RS
Stenotrophomonas maltophilia SS
11C Stenotrophomonas maltophilia RS
12 Pseudomonas aeruginosa SS SS
RS SR
ESBL-Proteus mirabilis RRS SR
13 Pseudomonas putida SS RS
Acinetobacter spp RRR I R S I
14 Serratia marcescens SSS SS
Acinetobacter baumannii RR RR S R
15A Morganella morganii RSS SS
Proteus mirabilis RRR SR
15B Glucose non-fermenting bacilli R R R R I
16 Stenotrophomonas maltophilia SS
Pseudomonas aeruginosa RR SS
17 Acinetobacter lwoffii SS S
Pseudomonas aeruginosa SS S
18A Escherichia coli RS S
18B Acinetobacter baumannii RI SR R
18D Stenotrophomonas maltophilia S
19 Escherichia coli SSS S
Enterobacter cloacae SSS S R
21 Enterobacter aerogenes IISS S
RRS SS
Abbreviations: ROC, ceftriaxone; CAZ, ceftazidime; MAX, cefepime; MEP, meropenem; CIP, ciprofloxacin; AMP-SBM, ampicillin-subactam; TIG, tigecycline; TMP-SMX,
trimethoprime-sulfamethoxazole; LEV, levofloxacin; ESBL, extended spectrum b-lactamase; R, resistant; I, intermediate; S, susceptible
Note: ESBL-producing Escherichia coli was suspected by the disk-diffusion susceptibility test [10].
Non-Cephalosporin-susceptible Gram-negative bacteria (GNB) were used to describe isolates that were non-susceptible to ceftriaxone, ceftazidime, and cefepime.
Intermediate and resistant isolates were considered non-susceptible [11]. Multi-drugs resistant (MDR) GNB was used to describe isolates that were non-
susceptible to all antibiotics routinely tested including amikacin, (ampicillin-sulbactam in A. baumannii), ceftriaxone, ceftazidime, cefepime, ciprofloxacin,
imepenem, and meropenem [12,13]. The antimicrobial susceptibilities TMP-SMX, ciprofloxacin, levofloxacin, and moxifloaxcin of the Stenotrophomonas maltophilia
strains isolated from the cerebrospinal fluid were determined concomitantly by the broth dilution method as described in the Clinical and Laboratory Standards
(CLSI) guidelines.
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Page 6 of 8infection of Case 18, anaerobic pathogens appeared and
metronidazole was administered thereafter.
The appearance of anaerobic pathogens may also pose
a therapeutic challenge because metronidazole is not a
regular antimicrobial agent used in ABM treatment [3-7].
Other complicated super-infections in ABM were noted
in Cases 11 and 18, in which Candida spp was the impli-
cated pathogen. This uncommon super-infection was
also noted in the report of Gelfand et al. [2]. Chronic use
of broad spectrum antimicrobial agents is an important
factor known to encourage the colonization of Candida
organisms. Antifungal agents should be used for such an
uncommon super-infection in treating ABM.
With an effort of management, the therapeutic result
of super-infection ABM showed that 95.2% (20/21) of
the involved patients belonged to the poor prognosis
group. The mortality rate of this specific group of ABM
patients is high (33.3%, 7/21) and survivors also have a
high incidence of severe morbidity. Because most
patients with super-infection ABM have both a preced-
ing neurosurgical event and a pre-existing bacterial
meningitis, it is difficult to assess the therapeutic out-
come of this uncommon infectious state.
Conclusions
Super-infection in ABM is usually seen in patients with
preceding neurosurgical event, including insertion of an
external ventricular drainage device. Fever recurrence is
the most common presentation and most new evidences
are non-specific. Repeat CSF culture study is needed for
diagnostic confirmation. The occurrence of super-infec-
tion in ABM has a great impact on the ABM treatment
because a high percentage of the implicated bacteria
strains are non-susceptible to common antibiotics used
and early detection is important for adjusting the anti-
biotic regimen. Infections by unusual pathogens like
anaerobes and fungi may appear and these deserve spe-
cial attention because the choice of antimicrobials will
be different. Because the pre-existing neurosurgical con-
dition is complicated by super-infection, prognosis of
super-infection in ABM remains poor. The interpreta-
tion of clinical data shown in this study is limited by its
small case series and the retrospective data collection in
a single hospital-based study. Further large-scale study is
needed for better delineation of the presentation and
prognosis.
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